AUG 10, 2016 10:15 AM PDT

Lower dose of beta blockers may save lives

"We set out on a mission to show if you treat patients with the doses that were used in the clinical trials, they will do better," says Jeffrey Goldberger. "We expected to see patients treated with the lower doses to have worse survival. We were shocked to discover they survived just as well, and possibly even better." (Credit: C x 2/Flickr)

Heart attack patients treated with a substantially lower dosage of beta-blockers survive at the same—or in some cases an even better—rate than patients on higher doses.

In fact, a new study shows that patients who receive one-fourth of the original clinical trial dose had up to a 20 to 25 percent decrease in mortality compared to the full dose group.

About 90 percent of patients who have had a heart attack currently receive beta-blockers, a class of drug commonly prescribed to improve survival and prevent future heart attacks. Beta-blockers block the effects of adrenaline on the heart, reduce irregular heartbeat (arrhythmia), and help prevent heart failure.

No one was more surprised at the results than lead investigator Jeffrey Goldberger, professor of medicine in cardiology at Northwestern University. He launched the study when he discovered heart attack patients were being treated with much lower doses of beta-blockers than were used in clinical trials.

“I thought that was terrible quality of care,” says Goldberger. “We set out on a mission to show if you treat patients with the doses that were used in the clinical trials, they will do better. We expected to see patients treated with the lower doses to have worse survival. We were shocked to discover they survived just as well, and possibly even better.”

He says new research should be conducted to determine the most appropriate beta-blocker dose for individual patients to get the optimal benefit. The earlier clinical trials did not assess the effects of different doses.

Patients are treated with lower doses for a variety of reasons. There may be concern about possible side effects that may include fatigue, sexual dysfunction, and depression. In addition, when patients are started on conservative, low doses in the hospital after a heart attack, they return home so quickly, there is little time to adjust the dosage.

The new study, published in the Journal of the American College of Cardiology, examined data in a multicenter registry on 6,682 patients who had a heart attack. About 90 percent were receiving beta-blockers. All the patients on beta-blockers survived longer than those who did not receive the drugs. The raw, unadjusted data showed that of the people who received the full dose, 14.7 percent died within two years; of those receiving the half dose, 12.9 percent died; for the quarter dose, 9.5 percent died; and for the one-eighth dose, 11.5 percent died.

OBTAIN (Outcomes of Beta-Blocker Therapy After Myocardial Infarction) is an observational multicenter registry in which beta-blocker dosing information was collected in patients with an acute heart attack at participating centers to assess the effect of dose on survival.

“There is probably not one right dose for every single patient,” Goldberger says. “It doesn’t make sense that the same dose will work for an 80-year-old frail man who had a small heart attack as a burly 40-year-old man with a huge heart attack.

“We now need to figure out how to dose it in individual patients. That’s something no one has considered in the decades that we have been using this medication. This huge gap in knowledge has been completely unexplored. Since this is medicine we use in every single heart attack patient, we ought to figure out how to use it properly.”

The National Heart, Lung and Blood Institute at the National Institutes of Health supported the work.

Source: Northwestern University

This article was originally published on futurity.org.
About the Author
  • Futurity features the latest discoveries by scientists at top research universities in the US, UK, Canada, Europe, Asia, and Australia. The nonprofit site, which launched in 2009, is supported solely by its university partners (listed below) in an effort to share research news directly with the public.
You May Also Like
JUL 18, 2020
Cardiology
Diagnosing Arterial Stenosis with Computational Modeling
JUL 18, 2020
Diagnosing Arterial Stenosis with Computational Modeling
Our understanding of cardiovascular health has increased by leaps and bounds. One of the few issues that lag behind the ...
AUG 13, 2020
Cardiology
Using Artificial Intelligence to Read Your ECG Results
AUG 13, 2020
Using Artificial Intelligence to Read Your ECG Results
An electrocardiogram (ECG) is a tool used to measure the heartbeat using an electrical current. By following the current ...
AUG 14, 2020
Cancer
Controlling Tumor Blood Flow to Increase Therapy Effectiveness
AUG 14, 2020
Controlling Tumor Blood Flow to Increase Therapy Effectiveness
Nowadays, most cancer drugs target a protein or inhibit a critical cellular process. Modern therapies have varying level ...
NOV 01, 2020
Neuroscience
Depression Increases Risk of Having a Stroke
NOV 01, 2020
Depression Increases Risk of Having a Stroke
Researchers in Alabama have found that people who suffer from multiple depressive symptoms are at an increased risk of h ...
NOV 12, 2020
Cardiology
Creating a Mouse Model to Test RBM20 Dependent Dilated Cardiomyopathy
NOV 12, 2020
Creating a Mouse Model to Test RBM20 Dependent Dilated Cardiomyopathy
Cardiovascular disease is something that, in most cases, is within our ability to control. A healthy diet and active lif ...
NOV 24, 2020
Cardiology
Patients on Statins Get the 'Nocebo Effect'
NOV 24, 2020
Patients on Statins Get the 'Nocebo Effect'
Millions of people around the world take statins to treat high cholesterol, which are estimated to reduce the risk of he ...
Loading Comments...